Skip to content

Study · Systematic review · 2026

5 results

Role of Dual GIP and GLP-1 Receptor Agonist, Tirzepatide in the Management of Weight Loss; A Systematic Review.

Rangraze IR, Khan S, Wali AF, Menezes G, Goud M, Jabran M

Current drug safety1 Jan 2026Cited by 1 (Europe PMC)

PMID39484756 (opens in a new tab)DOI10.2174/0115748863330434241015125302 (opens in a new tab)PepBankPUB-39484756
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a systematic review, seven phase 3 trials showed significant, dose-dependent reductions in body weight with tirzepatide.

    In plain wordsA review of seven large trials found that tirzepatide reduced body weight, with larger reductions at higher doses.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight reduction
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Seven phase 3 trials showed significant, dose-dependent reductions in body weight and improvements in metabolic markers.
    1 context sentence
    Summary · context
    Included RCTs and observational studies.
  2. 02HumanSystematic reviewEfficacy outcome

    In a systematic review, seven phase 3 trials of tirzepatide showed improvements in metabolic markers.

    In plain wordsA review of seven large trials found that metabolic markers improved with tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedMetabolic markers
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Seven phase 3 trials showed significant, dose-dependent reductions in body weight and improvements in metabolic markers.
    1 context sentence
    Summary · context
    Included RCTs and observational studies.
  3. 03HumanSystematic reviewSafety outcome

    In a systematic review, tirzepatide was well tolerated.

    In plain wordsA review reported that tirzepatide was well tolerated.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedTolerability
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Well-tolerated
    1 context sentence
    Summary · context
    Included RCTs and observational studies.
  4. 04HumanSystematic reviewSafety outcome

    In a systematic review, tirzepatide was linked to low rates of hypoglycemia.

    In plain wordsA review reported low rates of low blood sugar with tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedHypoglycemia
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    with low rates of hypoglycemia.
    1 context sentence
    Summary · context
    Included RCTs and observational studies.
  5. 05HumanSystematic reviewEfficacy outcome

    In a systematic review, subgroups with higher BMI had greater benefits with tirzepatide.

    In plain wordsA review reported that people with higher BMI gained greater benefits from tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedGreater benefit in higher-BMI subgroups
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Subgroups with higher BMI had greater benefits.
    1 context sentence
    Summary · context
    Included RCTs and observational studies.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.